US20160355677A1 - Toughened polylactic acid polymers and copolymers - Google Patents

Toughened polylactic acid polymers and copolymers Download PDF

Info

Publication number
US20160355677A1
US20160355677A1 US15/242,993 US201615242993A US2016355677A1 US 20160355677 A1 US20160355677 A1 US 20160355677A1 US 201615242993 A US201615242993 A US 201615242993A US 2016355677 A1 US2016355677 A1 US 2016355677A1
Authority
US
United States
Prior art keywords
composition
poly
copolymer
pla
polylactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/242,993
Inventor
Said Rizk
David P. Martin
Kicherl Ho
Amit Ganatra
Simon F. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tepha Inc
Original Assignee
Tepha Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tepha Inc filed Critical Tepha Inc
Priority to US15/242,993 priority Critical patent/US20160355677A1/en
Assigned to TEPHA, INC. reassignment TEPHA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GANATRA, AMIT, HO, KICHERL, MARTIN, DAVID P., RIZK, SAID, WILLIAMS, SIMON F.
Publication of US20160355677A1 publication Critical patent/US20160355677A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/06At least partially resorbable materials
    • A61L17/10At least partially resorbable materials containing macromolecular materials
    • A61L17/105Polyesters not covered by A61L17/12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/06At least partially resorbable materials
    • A61L17/10At least partially resorbable materials containing macromolecular materials
    • A61L17/12Homopolymers or copolymers of glycolic acid or lactic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04Macromolecular materials
    • A61L29/049Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04Macromolecular materials
    • A61L29/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/041Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/18Materials at least partially X-ray or laser opaque
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/01Use of inorganic substances as compounding ingredients characterized by their specific function
    • C08K3/014Stabilisers against oxidation, heat, light or ozone
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016Plasticisers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/005Stabilisers against oxidation, heat, light, ozone
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0083Nucleating agents promoting the crystallisation of the polymer matrix

Definitions

  • the present invention generally relates to polymeric compositions that can be processed into various extruded as well as molded forms, including fibers, tubes, films, nonwovens, injection molded or thermoformed components, which products have substantially uniform physical properties, and physical and thermo-mechanical integrity.
  • the compositions comprise polylactic acid polymers or copolymers and polymers or copolymers comprising 4-hydroxybutyrate.
  • Polylactic acid is an aliphatic polyester that can be prepared, for example, by direct condensation of lactic acid, azeotropic dehydrative condensation, and by ring-opening polymerization of lactide. In the latter case, the product is sometimes referred to as polylactide.
  • the relative proportions of the optically active enantiomers, D- and L-lactic acids, which are incorporated into the polymer, determine the specific properties of PLA. Varying the enantiomer proportions can result in polymer compositions that are amorphous or up to about 40% crystalline, with glass transition temperatures (Tg) ranging from about 50° C. to 80° C., and melting points (Tm) ranging from about 130° C. to 180° C.
  • Tg glass transition temperatures
  • Tm melting points
  • Elongation at break of poly-L-lactic acid is, however, typically just several percent.
  • the polymer has a glass transition temperature well above room temperature, and therefore shaped objects of PLLA tend to be brittle and glassy at room temperature.
  • Several methods have been used to increase the elongation at break of PLLA. Melt processing of the polymer, followed by orientation at temperatures above the glass transition temperature, can result in shaped objects with somewhat improved elongation to break. However, these objects are generally stiff due to the relatively high tensile modulus of the polymer.
  • incorporation of D-lactic acid in combination with orientation can yield further improvement.
  • incorporation of D-lactic acid at a level of 2% in an oriented film increases the elongation at break to 5-10%. The latter may be further increased to 78-97% with incorporation of about 6% D-lactic acid.
  • Orientation and incorporation of D-lactic acid has also been used to improve the toughness of fibers of PLA. Melt extruded fibers of PLA with elongation to break of 50-60% are commercially available under the trade name of IngeoTM PLA (Cargill, Minn.). The modulus of these objects is however still relatively high.
  • Blends of PLA with other polymers and additives have also investigated blends of PLA with other polymers and additives to improve PLA properties, for example, to improve toughness and decrease the stiffness.
  • blends of PLA with other PLAs and copolymers polycaprolactone, poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV), poly-R-3-hydroxybutyrate (PHB), poly-R,S-3-hydroxybutyrate, poly-3-hydroxyoctanoate, poly(hexamethylenesuccinate), poly(butylene succinate), poly(ethylene/butylene succinate), poly(ethylene oxide), poly(phosphazene), poly(sebacic anhydride), poly(vinyl alcohol), and poly(vinyl acetate) have all been reported (Tsuji, H., Polyesters, III, 4:129-177 (2002)).
  • Blends of PLA comprising multiple components have also been reported.
  • U.S. Pat. No. 5,939,467 to Wnuk et al. discloses blends comprising PLA, polyhydroxyalkanoates, and polyurethane or polycaprolactone.
  • Toughened compositions of PLA and PLA copolymers are disclosed, which also have low tensile modulus values and greater elongation to break. These toughened compositions are prepared by blending PLA and PLA copolymers with poly-4-hydroxybutyrate, and copolymers thereof. Blending of poly-4-hydroxybutyrate with PLA and its copolymers has been found to impart advantageous properties to the resulting blend. These compositions, and objects formed from these compositions, have improved toughness and lower stiffness than polylactic acid polymers or copolymers alone.
  • FIG. 1 is the chemical structure of poly-4-hydroxybutyrate (P4HB, TephaFLEX® biomaterial).
  • FIG. 2 shows some of the known biosynthetic pathways for the production of P4HB.
  • Pathway enzymes are: 1. Succinic semialdehyde dehydrogenase; 2. 4-hydroxybutyrate dehydrogenase; 3. diol oxidoreductase; 4. aldehyde dehydrogenase; 5. Coenzyme A transferase and 6. PHA synthetase.
  • Toughened blends comprising PLA and its copolymers have been developed that have improved properties.
  • Poly-4-hydroxybutyrate as generally used herein means a homopolymer comprising 4-hydroxybutyrate units. It may be referred to herein as P4HB or TephaFLEX® biomaterial (manufactured by Tepha, Inc., Cambridge, Mass.).
  • Copolymers of poly-4-hydroxybutyrate as generally used herein means any polymer comprising 4-hydroxybutyrate with one or more different hydroxy acid units.
  • “Blend” as generally used herein means a physical combination of different polymers, as opposed to a copolymer comprised of two or more different monomers which are linked by polymerization.
  • Toughness means a property of a material by virtue of which it can absorb energy; the actual work per unit volume or unit mass of material that is required to rupture it. Toughness is usually proportional to the area under the load-elongation curve such as the tensile stress-strain curve. (Rosato's Plastics Encyclopedia and Dictionary, Oxford Univ. Press, 1993.)
  • “Stiffness” means a property of the material to resist a change in shape. For fibers, this is typically measured as the tensile modulus or Young's modulus and is the initial slope of the stress strain curve. For other shaped articles, like molded goods, the stiffness could relate to the ability of the material to resist bending.
  • “Elongation” or extensibility of a material means the amount of increase in length resulting from, as an example, the tension to break a specimen. It is expressed usually as a percentage of the original length. (Rosato's Plastics Encyclopedia and Dictionary, Oxford Univ. Press, 1993.)
  • PLA refers to a polymer comprising a lactic acid monomer unit.
  • the polymer may be referred to as polylactic acid or polylactide. It may be a homopolymer or copolymer.
  • the lactic acid repeating units can be L-lactic acid, D-lactic acid, or D,L-lactic acid. Copolymers may also comprise monomeric units other than lactic acid, such as, but not limited to, glycolic acid.
  • Molecular weight refers to the weight average molecular weight (Mw) as opposed to the number average molecular weight (Mn).
  • ABSOR as generally used herein means the material is broken down in the body and eventually eliminated from the body.
  • Biocompatible as generally used herein means the biological response to the material or device being appropriate for the device's intended application in vivo. Any metabolites of these materials should also be biocompatible.
  • Compostable as generally used herein means the ability of the material to undergo physical, chemical, thermal, and/or biological degradation in a municipal solid waste composting facility such that the material will break down into, or otherwise become part of, usable finished compost.
  • the polylactic acid or polylactide polymers (together referred to as “PLA”) comprise a lactic acid monomeric unit, which may be L-lactic acid, D-lactic acid, or a mixture of D,L-lactic acid.
  • PLA polymers include polylactic acid sold by Natureworks® (Cargill, Minn.), Lacea® sold by Mitsui Chemical (Tokyo, Japan), and Resomer sold by Boehringer Ingelheim (Ingelheim Am Rhein, Germany).
  • the PLA is in a semi-crystalline form with at least 80 mole percent of the repeating unit being either L-lactide or D-lactide, and even more preferably 95 mole percent. If desired more than one PLA composition may be used.
  • PLA copolymers may also comprise monomeric units other than lactic acid.
  • a preferred PLA copolymer comprises glycolic acid, and is available commercially, for example, under the Vicryl® trade name.
  • P4HB poly-4-hydroxybutyrate
  • Poly-4-hydroxybutyrate is a strong, pliable thermoplastic polyester that is produced by a fermentation process, as described in U.S. Pat. No. 6,548,569 to Williams et al. Despite its biosynthetic route, the structure of the polyester is relatively simple ( FIG. 1 ).
  • the polymer belongs to a larger class of materials called polyhydroxyalkanoates (PHAs) that are produced by numerous microorganisms (see: Steinbüchel A., et al. Diversity of Bacterial Polyhydroxyalkanoic Acids, FEMS Microbial. Lett. 128:219-228 (1995)).
  • polyesters are produced as storage granules inside cells, and serve to regulate energy metabolism. They are also of commercial interest because of their thermoplastic properties, and relative ease of production.
  • biosynthetic routes are currently known to produce P4HB, as shown in FIG. 2 . Chemical synthesis of P4HB has been attempted, but it has been impossible to produce the polymer with a sufficiently high molecular weight necessary for most applications (Hori, Y., et al., Polymer 36:4703-4705 (1995)).
  • Copolymers of P4HB include 4-hydroxybutyrate copolymerized with 3-hydroxybutyrate or glycolic acid (U.S. Patent Publication No. 20030211131 by Martin & Skraly, U.S. Pat. No. 6,316,262 to Huisman et al., and U.S. Pat. No. 6,323,010 to Skraly et al.). Methods to control molecular weight of PHA polymers are disclosed by U.S. Pat. No. 5,811,272 to Snell et al.
  • PHAs with degradation rates in vivo of less than one year are disclosed by U.S. Pat. No. 6,548,569 to Williams et al. and WO 99/32536 by Martin et al.
  • Applications of P4HB have been reviewed in Williams, S. F., et al., Polyesters, III, 4:91-127 (2002), and by Martin, D. et al. Medical Applications of Poly-4-hydroxybutyrate: A Strong Flexible Absorbable Biomaterial, Biochem. Eng. J. 16:97-105 (2003). Medical devices and applications of P4HB have also been disclosed by WO 00/56376 by Williams et al.
  • the toughened PLA compositions may comprise other materials in addition to the polymers described above, including plasticizers, nucleants, and compatibilizers.
  • plasticizers are disclosed by U.S. Pat. No. 6,905,987 to Noda et al.
  • other components may be added to impart benefits such as, but not limited to, the following: stability including oxidative stability, brightness, color, flexibility, resiliency, workability, processibility (by addition of processing aids), viscosity modifiers, and odor control.
  • Therapeutically, prophylactically or diagnostic agents may be added.
  • Active components, such as drugs, and other biologically active substances may be incorporated, for example, for controlled release of the drugs or other substances. It may also be advantageous to incorporate contrast agents, radiopaque markers, or radioactive substances.
  • fillers including materials such as titanium dioxide, calcium carbonate, hydroxyapatite, and tricalcium phosphate.
  • a toughened composition of a PLA polymer or PLA copolymer is prepared as follows.
  • a PLA polymer or PLA copolymer is selected and compounded in a predetermined ratio with a P4HB polymer or copolymer using a twin screw extruder.
  • other additives such as plasticizers, nucleants, and compatibilizers may be added.
  • the PLA polymer or copolymer will be present from 1% to 99%, by weight. The exact ratio of PLA to P4HB will be determined by the desired toughness and stiffness of the composition.
  • Increasing the quantity of P4HB in the blend will generally decrease the tensile modulus (stiffness) and increase the elongation to break of the composition (and also any shaped object derived from the composition).
  • the extrudate is cooled, and then cut into granules in a pelletizer.
  • the granules obtained may then be subsequently processed by melt or solvent processing techniques.
  • PLA compositions toughened with P4HB polymers or copolymers are characterized by increased elongation to break, and decreased stiffness.
  • compositions possess properties that are desirable in both processing and the final product.
  • the properties would be desirable in processing by extrusion, injection/compression/blow molding, coating, spinning, blowing, thermoforming, laser cutting, thermal welding and calendaring processes.
  • a person skilled in the art would recognize that the compositions are useful in any application where increased toughness, elongation and/or decreased stiffness is desired.
  • the compositions may also provide other desired properties such as increased melt strength, impact and aging characteristics, and be useful in any application where these properties are desired.
  • compositions may be used in commodity, industrial and medical applications. In the latter case, the compositions may be used to make partially or fully absorbable biocompatible medical devices.
  • biocompatible medical devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws, bone plates and bone plating systems, biocompatible coatings, rotator cuff repair devices, surgical mesh, medical textiles and drapes, repair patches, slings, cardiovascular patches, tissue engineering scaffolds, vascular grafts, vascular closure devices, catheter balloons, anti-adhesion devices, drug delivery devices, embolization particles, orthopedic pins, adhesion barriers, stents (including coronary stents, peripheral stents, carotid stents, biliary stents, gastroenterology stents, urology stents, and neurology stents), embolization coils, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices,
  • the devices can also be a shaped object used as or in packaging, personal hygiene products, bags, utensils, disposable and/or compostable articles, garments, surgical drapes, and gloves.
  • the shaped object can be a disposable article, compostable article, packaging, personal hygiene product, textile, fiber, film, molded object, bag, utensil, garment, surgical drape, or glove.
  • PLLA polymer Resomer L 214 lot #1012474, Boehringer Ingelheim, Germany
  • P4HB poly-4-hydroxybutyrate, Mw 178,000, 2.3 dl/g (IV) (Tepha, Inc., Cambridge, Mass.) using a Leistritz 18 mm twin screw extruder (24:1 L/D).
  • Compounding was undertaken at a temperature of 110° C. at the feed, and 230° C. at the die.
  • the polymers were mixed in the molten state, extruded into large diameter filament, quenched into a water bath set at 5-20° C., and cut into 2-5 mm length pellets.
  • the PLLA and P4HB were compounded in the following three different ratios by weight: PLLA (90%):P4HB (10%); PLLA (77.5%):P4HB (22.5%); and PLLA (10%):P4HB (90%).
  • PLLA polymer Resomer L 214 lot #1002260, Boehringer Ingelheim, Germany
  • P4HB poly-4-hydroxybutyrate, Mw 170,000, 2.1 dl/g (IV) Tepha, Inc., Cambridge, Mass.
  • the blends prepared in Example 1 were extruded into monofilament fiber using the following method.
  • the blends were dried under vacuum overnight to less than 0.01% (w/w) water.
  • Dried pellets of the blended polymers were fed into an extruder barrel of an AJA (Alex James Associates, Greer, S.C.) 3 ⁇ 4′′ single screw extruder (24:1 L:D, 3:1 compression) equipped with a Zenith type metering pump (0.16 cc/rev) and a die with a single hole spinneret (0.026′′, 2:1 L:D) under a blanket of nitrogen.
  • the 4 heating zones of the extruder were set at 140°, 190°, 200° and 205° C.
  • the block, metering pump and the die were maintained at a constant temperature, preferably 180-250° C. Pump discharge pressure was kept below 1500 psi by controlling the temperatures and the speed of the metering pump.
  • the fiber spinning system was set up with a drop zone, air quench zone, a guide roll, three winders and a pickup. The fiber was oriented in-line with extrusion by drawing it in a multi-stage process to provide improved physical properties with stretch ratios of 1 to 11X. The resulting spun extrudate filament was free from all melt irregularities.
  • the extrudate filament was then drawn through multistage orientation in a heated tube or heated oven or hot water, which was maintained at a temperature above the softening temperature of the extrudate filament and then quenched in a cold water bath without the filament touching any surface until it is sufficiently cooled.
  • Example 1 and Example 2 were dried as described in Example 3 and extruded into tubes with internal diameters (ID) of 1-1.4 mm, and outer diameters (OD) of 1.3-1.7 mm using the following equipment, 1.25′′ 3 heat zone, 24:1 L/D, 3:1 compression horizontal extruder connected to conventional tubing die with an air inlet port to control the ID of tubes.
  • a water trough for tube quenching, dual-plane laser gauge to measure OD in two planes and a puller were also used.
  • Extruder temperatures were controlled at 120° C. for the first zone, 240° C. for the second zone, 265° C. for the third zone and 248° C. for the die. Screw speed was controlled between 10-40 rpm and the die pressure was maintained at 1500 psi.
  • the quench trough was maintained at 10° C. and process air at 10-30 inch H 2 O pressure was used to obtain the intended tubing ID.

Abstract

Toughened compositions of PLA and PLA copolymers are disclosed, which also have low tensile modulus values and greater elongation to break. These toughened compositions are prepared by blending PLA and PLA copolymers with poly-4-hydroxybutyrate, and copolymers thereof. Blending of poly-4-hydroxybutyrate with PLA and its copolymers has been found to impart advantageous properties to the resulting blend. These compositions, and objects formed from these compositions, have improved toughness and lower stiffness than polylactic acid polymers or copolymers alone.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a divisional of U.S. Ser. No. 11/671,544, filed Feb. 6, 2007, which claims priority to U.S. Ser. No. 60/747,144 filed May 12, 2006, U.S. Ser. No. 60/765,840, filed Feb. 7, 2006 and U.S. Ser. No. 60/765,808 filed Feb. 7, 2006.
  • FIELD OF THE INVENTION
  • The present invention generally relates to polymeric compositions that can be processed into various extruded as well as molded forms, including fibers, tubes, films, nonwovens, injection molded or thermoformed components, which products have substantially uniform physical properties, and physical and thermo-mechanical integrity. The compositions comprise polylactic acid polymers or copolymers and polymers or copolymers comprising 4-hydroxybutyrate.
  • BACKGROUND OF THE INVENTION
  • Polylactic acid (PLA) is an aliphatic polyester that can be prepared, for example, by direct condensation of lactic acid, azeotropic dehydrative condensation, and by ring-opening polymerization of lactide. In the latter case, the product is sometimes referred to as polylactide. The relative proportions of the optically active enantiomers, D- and L-lactic acids, which are incorporated into the polymer, determine the specific properties of PLA. Varying the enantiomer proportions can result in polymer compositions that are amorphous or up to about 40% crystalline, with glass transition temperatures (Tg) ranging from about 50° C. to 80° C., and melting points (Tm) ranging from about 130° C. to 180° C.
  • Elongation at break of poly-L-lactic acid (PLLA) is, however, typically just several percent. The polymer has a glass transition temperature well above room temperature, and therefore shaped objects of PLLA tend to be brittle and glassy at room temperature. Several methods have been used to increase the elongation at break of PLLA. Melt processing of the polymer, followed by orientation at temperatures above the glass transition temperature, can result in shaped objects with somewhat improved elongation to break. However, these objects are generally stiff due to the relatively high tensile modulus of the polymer.
  • Incorporation of D-lactic acid in combination with orientation can yield further improvement. For example, incorporation of D-lactic acid at a level of 2% in an oriented film increases the elongation at break to 5-10%. The latter may be further increased to 78-97% with incorporation of about 6% D-lactic acid. Orientation and incorporation of D-lactic acid has also been used to improve the toughness of fibers of PLA. Melt extruded fibers of PLA with elongation to break of 50-60% are commercially available under the trade name of Ingeo™ PLA (Cargill, Minn.). The modulus of these objects is however still relatively high.
  • Polymer scientists have also investigated blends of PLA with other polymers and additives to improve PLA properties, for example, to improve toughness and decrease the stiffness. For example, blends of PLA with other PLAs and copolymers, polycaprolactone, poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV), poly-R-3-hydroxybutyrate (PHB), poly-R,S-3-hydroxybutyrate, poly-3-hydroxyoctanoate, poly(hexamethylenesuccinate), poly(butylene succinate), poly(ethylene/butylene succinate), poly(ethylene oxide), poly(phosphazene), poly(sebacic anhydride), poly(vinyl alcohol), and poly(vinyl acetate) have all been reported (Tsuji, H., Polyesters, III, 4:129-177 (2002)). Blends of PLA comprising multiple components have also been reported. For example, U.S. Pat. No. 5,939,467 to Wnuk et al. discloses blends comprising PLA, polyhydroxyalkanoates, and polyurethane or polycaprolactone. These approaches have met with varying levels of success because many polymers are immiscible when blended, creating undesirable phase separation during processing, and/or such blends exhibit poor mechanical properties. These difficulties are exacerbated in the processing of fibers and films, where processing time is often much shorter.
  • It would therefore be desirable to identify polymers that could be blended with PLA and its copolymers, which provide a blend with improved toughness and lower stiffness.
  • It is therefore an object of this invention to provide toughened blends of PLA and its copolymers.
  • It is another object of this invention to provide blends of PLA and its copolymers with lower stiffness values.
  • It is still yet another object of this invention to provide blends of PLA and its copolymers with increased elongation to break.
  • It is yet another object of this invention to provide blends of PLA and its copolymers that can be processed into shaped objects, such as fibers, films, molded items, and nonwovens.
  • SUMMARY OF THE INVENTION
  • Toughened compositions of PLA and PLA copolymers are disclosed, which also have low tensile modulus values and greater elongation to break. These toughened compositions are prepared by blending PLA and PLA copolymers with poly-4-hydroxybutyrate, and copolymers thereof. Blending of poly-4-hydroxybutyrate with PLA and its copolymers has been found to impart advantageous properties to the resulting blend. These compositions, and objects formed from these compositions, have improved toughness and lower stiffness than polylactic acid polymers or copolymers alone.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is the chemical structure of poly-4-hydroxybutyrate (P4HB, TephaFLEX® biomaterial).
  • FIG. 2 shows some of the known biosynthetic pathways for the production of P4HB. Pathway enzymes are: 1. Succinic semialdehyde dehydrogenase; 2. 4-hydroxybutyrate dehydrogenase; 3. diol oxidoreductase; 4. aldehyde dehydrogenase; 5. Coenzyme A transferase and 6. PHA synthetase.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Toughened blends comprising PLA and its copolymers have been developed that have improved properties.
  • I. Definitions
  • “Poly-4-hydroxybutyrate” as generally used herein means a homopolymer comprising 4-hydroxybutyrate units. It may be referred to herein as P4HB or TephaFLEX® biomaterial (manufactured by Tepha, Inc., Cambridge, Mass.).
  • “Copolymers of poly-4-hydroxybutyrate” as generally used herein means any polymer comprising 4-hydroxybutyrate with one or more different hydroxy acid units.
  • “Blend” as generally used herein means a physical combination of different polymers, as opposed to a copolymer comprised of two or more different monomers which are linked by polymerization.
  • “Toughness” means a property of a material by virtue of which it can absorb energy; the actual work per unit volume or unit mass of material that is required to rupture it. Toughness is usually proportional to the area under the load-elongation curve such as the tensile stress-strain curve. (Rosato's Plastics Encyclopedia and Dictionary, Oxford Univ. Press, 1993.)
  • “Stiffness” means a property of the material to resist a change in shape. For fibers, this is typically measured as the tensile modulus or Young's modulus and is the initial slope of the stress strain curve. For other shaped articles, like molded goods, the stiffness could relate to the ability of the material to resist bending.
  • “Elongation” or extensibility of a material means the amount of increase in length resulting from, as an example, the tension to break a specimen. It is expressed usually as a percentage of the original length. (Rosato's Plastics Encyclopedia and Dictionary, Oxford Univ. Press, 1993.)
  • “PLA” as used herein refers to a polymer comprising a lactic acid monomer unit. The polymer may be referred to as polylactic acid or polylactide. It may be a homopolymer or copolymer. The lactic acid repeating units can be L-lactic acid, D-lactic acid, or D,L-lactic acid. Copolymers may also comprise monomeric units other than lactic acid, such as, but not limited to, glycolic acid.
  • “Molecular weight” as used herein, unless otherwise specified, refers to the weight average molecular weight (Mw) as opposed to the number average molecular weight (Mn).
  • “Absorbable” as generally used herein means the material is broken down in the body and eventually eliminated from the body.
  • “Biocompatible” as generally used herein means the biological response to the material or device being appropriate for the device's intended application in vivo. Any metabolites of these materials should also be biocompatible.
  • “Compostable” as generally used herein means the ability of the material to undergo physical, chemical, thermal, and/or biological degradation in a municipal solid waste composting facility such that the material will break down into, or otherwise become part of, usable finished compost.
  • II. Polymeric Compositions
  • A. PLA Polymers
  • The polylactic acid or polylactide polymers (together referred to as “PLA”) comprise a lactic acid monomeric unit, which may be L-lactic acid, D-lactic acid, or a mixture of D,L-lactic acid. Examples of commercially available PLA polymers include polylactic acid sold by Natureworks® (Cargill, Minn.), Lacea® sold by Mitsui Chemical (Tokyo, Japan), and Resomer sold by Boehringer Ingelheim (Ingelheim Am Rhein, Germany). In a preferred embodiment, the PLA is in a semi-crystalline form with at least 80 mole percent of the repeating unit being either L-lactide or D-lactide, and even more preferably 95 mole percent. If desired more than one PLA composition may be used. For example, two PLA polymers with different molecular weights or melting temperatures may be used. PLA copolymers may also comprise monomeric units other than lactic acid. A preferred PLA copolymer comprises glycolic acid, and is available commercially, for example, under the Vicryl® trade name.
  • B. Polymers Comprising 4-Hydroxybutyrate
  • Tepha, Inc. of Cambridge, Mass. produces poly-4-hydroxybutyrate (P4HB) and copolymers thereof using transgenic fermentation methods. Poly-4-hydroxybutyrate is a strong, pliable thermoplastic polyester that is produced by a fermentation process, as described in U.S. Pat. No. 6,548,569 to Williams et al. Despite its biosynthetic route, the structure of the polyester is relatively simple (FIG. 1). The polymer belongs to a larger class of materials called polyhydroxyalkanoates (PHAs) that are produced by numerous microorganisms (see: Steinbüchel A., et al. Diversity of Bacterial Polyhydroxyalkanoic Acids, FEMS Microbial. Lett. 128:219-228 (1995)). In nature these polyesters are produced as storage granules inside cells, and serve to regulate energy metabolism. They are also of commercial interest because of their thermoplastic properties, and relative ease of production. Several biosynthetic routes are currently known to produce P4HB, as shown in FIG. 2. Chemical synthesis of P4HB has been attempted, but it has been impossible to produce the polymer with a sufficiently high molecular weight necessary for most applications (Hori, Y., et al., Polymer 36:4703-4705 (1995)).
  • Copolymers of P4HB include 4-hydroxybutyrate copolymerized with 3-hydroxybutyrate or glycolic acid (U.S. Patent Publication No. 20030211131 by Martin & Skraly, U.S. Pat. No. 6,316,262 to Huisman et al., and U.S. Pat. No. 6,323,010 to Skraly et al.). Methods to control molecular weight of PHA polymers are disclosed by U.S. Pat. No. 5,811,272 to Snell et al.
  • PHAs with degradation rates in vivo of less than one year are disclosed by U.S. Pat. No. 6,548,569 to Williams et al. and WO 99/32536 by Martin et al. Applications of P4HB have been reviewed in Williams, S. F., et al., Polyesters, III, 4:91-127 (2002), and by Martin, D. et al. Medical Applications of Poly-4-hydroxybutyrate: A Strong Flexible Absorbable Biomaterial, Biochem. Eng. J. 16:97-105 (2003). Medical devices and applications of P4HB have also been disclosed by WO 00/56376 by Williams et al.
  • C. Other Components
  • The toughened PLA compositions may comprise other materials in addition to the polymers described above, including plasticizers, nucleants, and compatibilizers. Non-limiting examples of plasticizers are disclosed by U.S. Pat. No. 6,905,987 to Noda et al. In addition, other components may be added to impart benefits such as, but not limited to, the following: stability including oxidative stability, brightness, color, flexibility, resiliency, workability, processibility (by addition of processing aids), viscosity modifiers, and odor control. Therapeutically, prophylactically or diagnostic agents may be added. Active components, such as drugs, and other biologically active substances may be incorporated, for example, for controlled release of the drugs or other substances. It may also be advantageous to incorporate contrast agents, radiopaque markers, or radioactive substances. For certain applications it may also be desirable to incorporate fillers, including materials such as titanium dioxide, calcium carbonate, hydroxyapatite, and tricalcium phosphate.
  • III. Methods of Making Toughened Compositions of PLA and PLA Copolymers
  • In a preferred method, a toughened composition of a PLA polymer or PLA copolymer is prepared as follows. A PLA polymer or PLA copolymer is selected and compounded in a predetermined ratio with a P4HB polymer or copolymer using a twin screw extruder. If desired, other additives, such as plasticizers, nucleants, and compatibilizers may be added. Typically, the PLA polymer or copolymer will be present from 1% to 99%, by weight. The exact ratio of PLA to P4HB will be determined by the desired toughness and stiffness of the composition. Increasing the quantity of P4HB in the blend will generally decrease the tensile modulus (stiffness) and increase the elongation to break of the composition (and also any shaped object derived from the composition). The extrudate is cooled, and then cut into granules in a pelletizer. The granules obtained may then be subsequently processed by melt or solvent processing techniques.
  • PLA compositions toughened with P4HB polymers or copolymers are characterized by increased elongation to break, and decreased stiffness.
  • IV. Fabrication with Toughened PLA Compositions
  • The compositions possess properties that are desirable in both processing and the final product. For example, the properties would be desirable in processing by extrusion, injection/compression/blow molding, coating, spinning, blowing, thermoforming, laser cutting, thermal welding and calendaring processes. A person skilled in the art would recognize that the compositions are useful in any application where increased toughness, elongation and/or decreased stiffness is desired. The compositions may also provide other desired properties such as increased melt strength, impact and aging characteristics, and be useful in any application where these properties are desired.
  • The compositions may be used in commodity, industrial and medical applications. In the latter case, the compositions may be used to make partially or fully absorbable biocompatible medical devices. Such devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws, bone plates and bone plating systems, biocompatible coatings, rotator cuff repair devices, surgical mesh, medical textiles and drapes, repair patches, slings, cardiovascular patches, tissue engineering scaffolds, vascular grafts, vascular closure devices, catheter balloons, anti-adhesion devices, drug delivery devices, embolization particles, orthopedic pins, adhesion barriers, stents (including coronary stents, peripheral stents, carotid stents, biliary stents, gastroenterology stents, urology stents, and neurology stents), embolization coils, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, intracardiac septal defect repair devices (including, but not limited to, atrial septal defect repair devices and PFO closure devices, and left atrial appendage (LAA) closure devices), pericardial patches, bulking and filling agents, vein valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion cages, imaging devices, skin substitutes, dural substitutes, bone graft substitutes, bone dowels, wound dressings, and hemostats.
  • The devices can also be a shaped object used as or in packaging, personal hygiene products, bags, utensils, disposable and/or compostable articles, garments, surgical drapes, and gloves. The shaped object can be a disposable article, compostable article, packaging, personal hygiene product, textile, fiber, film, molded object, bag, utensil, garment, surgical drape, or glove.
  • The present invention will be further understood by reference to the following non-limiting examples.
  • EXAMPLES Example 1 Preparation of a Blend of PLA Polymer and P4HB Polymer
  • PLLA polymer (Resomer L 214 lot #1012474, Boehringer Ingelheim, Germany) with a viscosity of 5.9 dl/g (IV) was compounded with P4HB (poly-4-hydroxybutyrate, Mw 178,000, 2.3 dl/g (IV) (Tepha, Inc., Cambridge, Mass.) using a Leistritz 18 mm twin screw extruder (24:1 L/D). Compounding was undertaken at a temperature of 110° C. at the feed, and 230° C. at the die. The polymers were mixed in the molten state, extruded into large diameter filament, quenched into a water bath set at 5-20° C., and cut into 2-5 mm length pellets. The PLLA and P4HB were compounded in the following three different ratios by weight: PLLA (90%):P4HB (10%); PLLA (77.5%):P4HB (22.5%); and PLLA (10%):P4HB (90%).
  • Example 2 Preparation of a Blend of PLA Polymer and P4HB Polymer
  • PLLA polymer (Resomer L 214 lot #1002260, Boehringer Ingelheim, Germany) with a high intrinsic viscosity of 7.0 dl/g (IV) was dry mixed with P4HB (poly-4-hydroxybutyrate, Mw 170,000, 2.1 dl/g (IV) Tepha, Inc., Cambridge, Mass.) by tumble mixing at room temperature. The PLLA and P4HB were compounded in the following three different ratios by weight:
  • PLLA (90%):P4HB (10%); PLLA (77.5%):P4HB (22.5%); and PLLA (10%):P4HB (90%). Example 3 Fiber Extrusion of PLA/P4HB Blends
  • The blends prepared in Example 1 were extruded into monofilament fiber using the following method. The blends were dried under vacuum overnight to less than 0.01% (w/w) water. Dried pellets of the blended polymers were fed into an extruder barrel of an AJA (Alex James Associates, Greer, S.C.) ¾″ single screw extruder (24:1 L:D, 3:1 compression) equipped with a Zenith type metering pump (0.16 cc/rev) and a die with a single hole spinneret (0.026″, 2:1 L:D) under a blanket of nitrogen. The 4 heating zones of the extruder were set at 140°, 190°, 200° and 205° C. The block, metering pump and the die were maintained at a constant temperature, preferably 180-250° C. Pump discharge pressure was kept below 1500 psi by controlling the temperatures and the speed of the metering pump. The fiber spinning system was set up with a drop zone, air quench zone, a guide roll, three winders and a pickup. The fiber was oriented in-line with extrusion by drawing it in a multi-stage process to provide improved physical properties with stretch ratios of 1 to 11X. The resulting spun extrudate filament was free from all melt irregularities. To provide optimal physical properties to fiber, the extrudate filament was then drawn through multistage orientation in a heated tube or heated oven or hot water, which was maintained at a temperature above the softening temperature of the extrudate filament and then quenched in a cold water bath without the filament touching any surface until it is sufficiently cooled.
  • Oriented monofilament fiber produced according to the procedure of Example 3 was tested on a MTS Mechanical Analyzer. The results are shown in Table 1 below.
  • TABLE 1
    Properties of PLLA:P4HB Blends at different ratios versus PLLA
    Elon-
    Diam- Break Break gation Young's Knot
    Sample (% eter Load Stress at Break Modulus Load
    by weight) (mm) (kgf) (kgf/mm2) (%) (kgf/mm2) (kgf)
    P4HB (90%): 0.309 5.05 67.4 24.3 170.9 3.01
    PLLA (10%)
    P4HB (22.5%): 0.312 2.92 36.9 17.0 270.4 2.07
    PLLA (77.5%)
    P4HB (10%): 0.382 4.02 35.2 16.7 302.1 2.89
    PLLA (90%)
    Reference: 0.106 0.6 66.0 3.0 700.0 Nd
    PLLA (100%)
  • It is evident from Table 1 that blending P4HB with PLLA increases the toughness of the PLLA (elongation at break increases), and decreases Young's modulus. The extent of these changes increases with increasing weight percentage of P4HB in the blend.
  • Note: The fibers in Table 1 have been oriented to increase the tensile strength of the fiber. Much of the elongation to break is reduced during the orientation process. (Higher elongation to break (>200%) for partially oriented tubes is disclosed in Example 4.)
  • Example 4 Tube Extrusion of PLA/P4HB Blends
  • The blends prepared in Example 1 and Example 2 were dried as described in Example 3 and extruded into tubes with internal diameters (ID) of 1-1.4 mm, and outer diameters (OD) of 1.3-1.7 mm using the following equipment, 1.25″ 3 heat zone, 24:1 L/D, 3:1 compression horizontal extruder connected to conventional tubing die with an air inlet port to control the ID of tubes. A water trough for tube quenching, dual-plane laser gauge to measure OD in two planes and a puller were also used. Extruder temperatures were controlled at 120° C. for the first zone, 240° C. for the second zone, 265° C. for the third zone and 248° C. for the die. Screw speed was controlled between 10-40 rpm and the die pressure was maintained at 1500 psi. During the extrusion the quench trough was maintained at 10° C. and process air at 10-30 inch H2O pressure was used to obtain the intended tubing ID.
  • The extruded tubes were tested on a MTS Mechanical Analyzer, the Mw's of the tubes were analyzed by Gel Permeation Chromatography (GPC) and the results are shown in Table 2.
  • TABLE 2
    Properties of tubing melt extruded from P4HB:PLLA blends
    (22.5:77.5% by weight).
    Elongation Tensile
    Mixing Mw by GPC OD ID To Break Strength
    Method g/mol (mm) (mm) (%) (MPa)
    Twin 285,000 1.547 ± 0.042 1.097 281 ± 69 33.5
    Screw
    Dry Blend 344,000 1.613 ± 0.029 1.363 206 ± 92 47.0

Claims (12)

We claim:
1. A medical device comprising a toughened polymer composition comprising poly-4-hydroxybutyrate homopolymer or copolymer thereof wherein the composition further comprises at least one polylactic acid homopolymer or copolymer, and the amount of poly-4-hydroxybutyrate homopolymer or copolymer added is sufficient to increase the elongation to break of the composition to greater than the elongation to break of the polylactic acid homopolymer or copolymer.
2. The medical device of claim 1 wherein the composition has been oriented.
3. The medical device of claim 1 wherein the elongation to break of the composition is greater than 3%.
4. The medical device of claim 3 wherein the elongation to break of the composition is between 3% and 281%.
5. The medical device of claim 1 wherein the Young's modulus of the composition is less than the Young's modulus of the polylactic acid homopolymer or copolymer.
6. The medical device of claim 5 wherein the Young's modulus of the composition is less than 700 kgf/mm2.
7. The medical device of claim 1 wherein the ratio of the polylactic acid homopolymer or copolymer to the poly-4-hydroxybutyrate homopolymer is between 9:1 and 1:9 by weight.
8. The medical device of claim 1 wherein the polylactic acid homopolymer is poly-L-lactic acid.
9. The medical device of claim 1 wherein the device is a suture, suture fastener, meniscus repair device, rivet, tack, staple, screw, bone plate, bone plating system, biocompatible coating, rotator cuff repair device, surgical mesh, medical textile, repair patch, sling, cardiovascular patch, tissue engineering scaffold, vascular graft, vascular closure device, catheter balloon, anti-adhesion device, drug delivery device, embolization particle, orthopedic pin, adhesion barrier, stent (including coronary stents, peripheral stents, carotid stents, biliary stents, gastroenterology stents, urology stents, and neurology stents), embolization coil, guided tissue repair/regeneration device, articular cartilage repair device, nerve guide, tendon repair device, intracardiac septal defect repair device (including, but not limited to, atrial septal defect repair devices and PFO closure devices and left atrial appendage (LAA) closure devices), pericardial patch, bulking and filling agent, vein valves, bone marrow scaffold, meniscus regeneration device, ligament graft, tendon graft, ocular cell implant, spinal fusion cage, imaging device, skin substitute, dural substitute, bone graft substitute, bone dowel, would dressing, or a hemostat.
10. A process for preparing the medical device of claim 1, comprising blending poly-4-hydroxybutyrate homopolymer or copolymer thereof with at least one polylactic acid homopolymer or copolymer, wherein the poly-4-hydroxybutyrate homopolymer or copolymer thereof and at least one polylactic acid homopolymer are mixed in the molten state at a temperature between 110° C. and 230° C., and extruded.
11. The process of claim 8 further comprising extruding the toughened composition, wherein the composition is dried to a water content of less than 0.01% (w/w) prior to extrusion, and wherein the composition is extruded at a temperature between 140° C. and 250° C.
12. The process of claim 9 wherein the extrudate is oriented by drawing it with stretch ratios of 1X to 11X.
US15/242,993 2006-02-07 2016-08-22 Toughened polylactic acid polymers and copolymers Abandoned US20160355677A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/242,993 US20160355677A1 (en) 2006-02-07 2016-08-22 Toughened polylactic acid polymers and copolymers

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76584006P 2006-02-07 2006-02-07
US76580806P 2006-02-07 2006-02-07
US74714406P 2006-05-12 2006-05-12
US11/671,544 US20070182041A1 (en) 2006-02-07 2007-02-06 Toughened Polylactic Acid Polymers and Copolymers
US15/242,993 US20160355677A1 (en) 2006-02-07 2016-08-22 Toughened polylactic acid polymers and copolymers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/671,544 Division US20070182041A1 (en) 2006-02-07 2007-02-06 Toughened Polylactic Acid Polymers and Copolymers

Publications (1)

Publication Number Publication Date
US20160355677A1 true US20160355677A1 (en) 2016-12-08

Family

ID=38189011

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/671,544 Abandoned US20070182041A1 (en) 2006-02-07 2007-02-06 Toughened Polylactic Acid Polymers and Copolymers
US11/671,632 Active 2027-12-02 US7618448B2 (en) 2006-02-07 2007-02-06 Polymeric, degradable drug-eluting stents and coatings
US15/242,979 Abandoned US20160355637A1 (en) 2006-02-07 2016-08-22 Toughened polylactic acid polymers and copolymers
US15/242,993 Abandoned US20160355677A1 (en) 2006-02-07 2016-08-22 Toughened polylactic acid polymers and copolymers

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/671,544 Abandoned US20070182041A1 (en) 2006-02-07 2007-02-06 Toughened Polylactic Acid Polymers and Copolymers
US11/671,632 Active 2027-12-02 US7618448B2 (en) 2006-02-07 2007-02-06 Polymeric, degradable drug-eluting stents and coatings
US15/242,979 Abandoned US20160355637A1 (en) 2006-02-07 2016-08-22 Toughened polylactic acid polymers and copolymers

Country Status (8)

Country Link
US (4) US20070182041A1 (en)
EP (2) EP1993621B1 (en)
JP (1) JP5508720B2 (en)
AT (1) ATE520425T1 (en)
AU (1) AU2007212501B2 (en)
CA (1) CA2640750C (en)
ES (2) ES2395112T3 (en)
WO (2) WO2007092418A2 (en)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521977A1 (en) * 2003-04-10 2004-10-21 Synthes (U.S.A.) Device for the temporary splinting of toes
GB0329654D0 (en) 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
US9452001B2 (en) * 2005-02-22 2016-09-27 Tecres S.P.A. Disposable device for treatment of infections of human limbs
WO2007024501A2 (en) 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
CA2625264C (en) 2005-10-13 2015-12-15 Synthes (U.S.A.) Drug-impregnated sleeve for a medical implant
WO2007092418A2 (en) * 2006-02-07 2007-08-16 Tepha, Inc. Polymeric, degradable drug-eluting stents and coatings
US9592325B2 (en) * 2006-02-07 2017-03-14 Tepha, Inc. Polymeric, degradable drug-eluting stents and coatings
US8979921B2 (en) * 2006-02-07 2015-03-17 Tepha, Inc. Polymeric, degradable drug-eluting stents and coatings
BRPI0600685A (en) * 2006-02-24 2007-11-20 Phb Ind Sa environmentally degradable polymeric blend and its process of obtaining
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US20080097620A1 (en) * 2006-05-26 2008-04-24 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US9089627B2 (en) 2006-07-11 2015-07-28 Abbott Cardiovascular Systems Inc. Stent fabricated from polymer composite toughened by a dispersed phase
IL177550A0 (en) * 2006-08-17 2006-12-31 Sialo Technology Israel Ltd All-in-one optical microscopic handle
DE602007011671D1 (en) 2006-11-30 2011-02-10 Smith & Nephew Inc FIBER REINFORCED COMPOSITE MATERIAL
US8814930B2 (en) 2007-01-19 2014-08-26 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
KR20120106880A (en) 2007-01-21 2012-09-26 헤모텍 아게 Medical product for treating stenosis of body passages and for preventing threatening restenosis
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
AU2008240418B2 (en) 2007-04-18 2013-08-15 Smith & Nephew Plc Expansion moulding of shape memory polymers
ATE505220T1 (en) 2007-04-19 2011-04-15 Smith & Nephew Inc GRAFT FIXATION
EP2142227B1 (en) 2007-04-19 2012-02-29 Smith & Nephew, Inc. Multi-modal shape memory polymers
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090112259A1 (en) * 2007-10-31 2009-04-30 Angiotech Pharmaceuticals, Inc. Recombinant expressed bioadsorbable polyhydroxyalkonate monofilament and multi-filaments self-retaining sutures
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US10898620B2 (en) 2008-06-20 2021-01-26 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof
US8206635B2 (en) * 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US8206636B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US9216152B2 (en) 2008-06-27 2015-12-22 Tepha, Inc. Injectable delivery of microparticles and compositions therefore
US8129477B1 (en) * 2008-08-06 2012-03-06 Medtronic, Inc. Medical devices and methods including blends of biodegradable polymers
US9314999B2 (en) 2008-08-15 2016-04-19 Toray Plastics (America), Inc. Biaxially oriented polylactic acid film with high barrier
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US20100244304A1 (en) * 2009-03-31 2010-09-30 Yunbing Wang Stents fabricated from a sheet with increased strength, modulus and fracture toughness
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
CA3186201A1 (en) 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US9150004B2 (en) * 2009-06-19 2015-10-06 Toray Plastics (America), Inc. Biaxially oriented polylactic acid film with improved heat seal properties
WO2010151872A1 (en) * 2009-06-26 2010-12-29 Toray Plastics (America) , Inc. Biaxially oriented polylactic acid film with improved moisture barrier
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
EP2453938B1 (en) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
CA2770885A1 (en) * 2009-08-27 2011-03-17 Metabolix, Inc. Toughened polyhydroxyalkanoate compositions
EP2480710B1 (en) 2009-09-25 2018-01-24 Toray Plastics (America) , Inc. Multi-layer high moisture barrier polylactic acid film and its method of forming
US8372133B2 (en) 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
WO2011103452A1 (en) 2010-02-19 2011-08-25 Toray Plastics (America) , Inc. Multi-layer high moisture barrier polylactic acid film
US9492962B2 (en) 2010-03-31 2016-11-15 Toray Plastics (America), Inc. Biaxially oriented polylactic acid film with reduced noise level and improved moisture barrier
WO2011123165A1 (en) 2010-03-31 2011-10-06 Toray Plastics (America), Inc. Biaxially oriented polyactic acid film with reduced noise level
US8981316B2 (en) * 2010-04-02 2015-03-17 Abbott Cardiovascular Systems Inc. Radiation sterilization of implantable medical devices
EP2425865A1 (en) * 2010-08-06 2012-03-07 Aesculap AG Medicinal thread having a polyhydroxyalkanoate coating
US8936740B2 (en) 2010-08-13 2015-01-20 Kimberly-Clark Worldwide, Inc. Modified polylactic acid fibers
US10753023B2 (en) * 2010-08-13 2020-08-25 Kimberly-Clark Worldwide, Inc. Toughened polylactic acid fibers
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8758374B2 (en) 2010-09-15 2014-06-24 University Of Utah Research Foundation Method for connecting nerves via a side-to-side epineurial window using artificial conduits
WO2012064526A1 (en) 2010-11-09 2012-05-18 Tepha, Inc. Drug eluting cochlear implants
US20140072610A1 (en) * 2011-03-21 2014-03-13 National University Of Singapore Bioabsorbable tracheal stent, and method of manufacturing thereof
US8545546B2 (en) 2011-05-13 2013-10-01 Abbott Cardiovascular Systems Inc. Bioabsorbable scaffolds made from composites
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US8680228B2 (en) * 2011-09-27 2014-03-25 Tepha, Inc. Controlled hydrolysis of poly-4-hydroxybutyrate and copolymers
US9180228B2 (en) 2011-10-03 2015-11-10 Abbott Cardiovascular Systems Inc. Rubber toughened bioresorbable polymer peripheral scaffolds
US10842494B2 (en) 2011-10-17 2020-11-24 University Of Utah Research Foundation Methods and devices for connecting nerves
US9931121B2 (en) 2011-10-17 2018-04-03 University Of Utah Research Foundation Methods and devices for connecting nerves
TWI590843B (en) 2011-12-28 2017-07-11 信迪思有限公司 Films and methods of manufacture
US8637130B2 (en) 2012-02-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Molded parts containing a polylactic acid composition
US10858762B2 (en) * 2012-02-10 2020-12-08 Kimberly-Clark Worldwide, Inc. Renewable polyester fibers having a low density
US8975305B2 (en) 2012-02-10 2015-03-10 Kimberly-Clark Worldwide, Inc. Rigid renewable polyester compositions having a high impact strength and tensile elongation
US9040598B2 (en) 2012-02-10 2015-05-26 Kimberly-Clark Worldwide, Inc. Renewable polyester compositions having a low density
US8980964B2 (en) 2012-02-10 2015-03-17 Kimberly-Clark Worldwide, Inc. Renewable polyester film having a low modulus and high tensile elongation
US9254212B2 (en) 2012-04-06 2016-02-09 Abbott Cardiovascular Systems Inc. Segmented scaffolds and delivery thereof for peripheral applications
WO2013176734A1 (en) 2012-05-21 2013-11-28 Tepha, Inc. Resorbable bioceramic compositions of poly-4-hydroxybutyrate and copolymers
US9475930B2 (en) 2012-08-17 2016-10-25 Metabolix, Inc. Biobased rubber modifiers for polymer blends
WO2014124562A1 (en) * 2013-02-18 2014-08-21 美亚无纺布工业有限公司 Degradable recycling material
US9290612B2 (en) 2013-03-13 2016-03-22 Tepha, Inc. Compositions and devices of poly-4-hydroxybutyrate
US10201640B2 (en) 2013-03-13 2019-02-12 Tepha, Inc. Ultrafine electrospun fibers of poly-4-hydroxybutyrate and copolymers thereof
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
US10669417B2 (en) 2013-05-30 2020-06-02 Cj Cheiljedang Corporation Recyclate blends
EP3010560B1 (en) 2013-06-21 2020-01-01 DePuy Synthes Products, Inc. Films and methods of manufacture
US9717609B2 (en) 2013-08-01 2017-08-01 Abbott Cardiovascular Systems Inc. Variable stiffness stent
WO2015026964A1 (en) 2013-08-20 2015-02-26 Tepha, Inc. Closed cell foams including poly-4-hydroxybutyrate and copolymers thereof
US9687585B2 (en) 2013-08-20 2017-06-27 Tepha, Inc. Thermoformed poly-4-hydroxybutyrate medical implants
US9302029B2 (en) 2013-10-31 2016-04-05 Tepha, Inc. Pultrusion of poly-4-hydroxybutyrate and copolymers thereof
WO2015069556A1 (en) 2013-11-05 2015-05-14 Tepha, Inc. Compositions and devices of poly-4-hydroxybutyrate
US9850377B2 (en) 2013-11-11 2017-12-26 Ineos Styrolution Group Gmbh Blends of styrene butadiene copolymers with poly(lactic acid)
US11154642B2 (en) 2013-12-26 2021-10-26 Tepha, Inc. Medical implants including laminates of poly-4-hydroxybutyrate and copolymers thereof
US9457127B2 (en) 2014-03-18 2016-10-04 Tepha, Inc. Micro-fiber webs of poly-4-hydroxybutyrate and copolymers thereof produced by centrifugal spinning
WO2015149029A1 (en) 2014-03-27 2015-10-01 Metabolix, Inc. Highly filled polymer systems
CA2947141C (en) 2014-04-30 2019-01-15 Tepha, Inc. Three-dimensional resorbable implants for tissue reinforcement and hernia repair
US9480588B2 (en) 2014-08-15 2016-11-01 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US10500303B2 (en) 2014-08-15 2019-12-10 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US9730819B2 (en) 2014-08-15 2017-08-15 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9259339B1 (en) 2014-08-15 2016-02-16 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9855156B2 (en) * 2014-08-15 2018-01-02 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
ES2661648T3 (en) 2014-08-20 2018-04-02 Tepha, Inc. Thermoformed poly-4-hydroxybutyrate medical implants
ES2802383T3 (en) 2014-09-22 2021-01-19 Tepha Inc Targeted P4HB implants containing antimicrobial agents
WO2016094669A1 (en) 2014-12-11 2016-06-16 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
WO2016160012A1 (en) 2015-04-01 2016-10-06 Yale University Iron platinum particles for adherence of biologics on medical implants
EP3313325B1 (en) * 2015-06-29 2023-09-06 Lyra Therapeutics, Inc. Implantable scaffolds for treatment of sinusitis
ES2873887T3 (en) 2016-05-16 2021-11-04 Elixir Medical Corp Stent release
US11622872B2 (en) 2016-05-16 2023-04-11 Elixir Medical Corporation Uncaging stent
ES2746375T3 (en) 2016-08-02 2020-03-05 Fitesa Germany Gmbh System and process for the preparation of polylactic acid nonwoven fabrics
US11441251B2 (en) 2016-08-16 2022-09-13 Fitesa Germany Gmbh Nonwoven fabrics comprising polylactic acid having improved strength and toughness
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut Biodegradable pressure sensor
EP3630445B1 (en) 2017-05-25 2022-11-30 Tepha, Inc. Continuous formation of tubes of poly-4-hydroxybutyrate and copolymers thereof
US10874498B2 (en) 2017-09-06 2020-12-29 Tepha, Inc. Calendered surgical meshes comprising polyhydroxyalkanoates
EP3459469A1 (en) 2017-09-23 2019-03-27 Universität Zürich Medical occluder device
WO2019112925A1 (en) 2017-12-04 2019-06-13 Tepha, Inc. Vacuum membrane thermoformed poly-4-hydroxybutyrate medical implants
CA3102277A1 (en) 2018-06-11 2019-12-19 Tepha, Inc. Methods for 3d printing of poly-4-hydroxybutyrate and copolymers
ES2956815T3 (en) 2018-10-29 2023-12-28 Tepha Inc Procedures for manufacturing mesh sutures from poly-4-hydroxybutyrate and its copolymers
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
US11745001B2 (en) 2020-03-10 2023-09-05 University Of Connecticut Therapeutic bandage
CN111234490A (en) * 2020-03-20 2020-06-05 珠海麦得发生物科技股份有限公司 High-toughness fully-degradable PHA/PLLA composite material and preparation method thereof
DE102020206085B4 (en) * 2020-05-14 2022-08-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Biodegradable stents coated with laminin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728839A (en) * 1971-04-29 1973-04-24 American Cyanamid Co Storage stable surgically absorbable polyglycolic acid products
US4950258A (en) * 1988-01-28 1990-08-21 Japan Medical Supply Co., Ltd. Plastic molded articles with shape memory property
EP0753539A1 (en) * 1995-07-13 1997-01-15 Mitsubishi Gas Chemical Company, Inc. Aliphatic polyester polymer blends based on poly(lactic acid), methods for manufacturing the same, and methods for molding the same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059211A (en) 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5527337A (en) 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
WO1992015342A1 (en) * 1991-03-08 1992-09-17 Keiji Igaki Stent for vessel, structure of holding said stent, and device for mounting said stent
US5939467A (en) * 1992-06-26 1999-08-17 The Procter & Gamble Company Biodegradable polymeric compositions and products thereof
US5384030A (en) * 1994-02-15 1995-01-24 General Motors Corporation Exhaust sensor including a composite tile sensing element and methods of making the same
US5629077A (en) 1994-06-27 1997-05-13 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
DE19539449A1 (en) * 1995-10-24 1997-04-30 Biotronik Mess & Therapieg Process for the production of intraluminal stents from bioresorbable polymer material
FR2748422B1 (en) 1996-05-10 1998-06-12 Rollin Sa SYSTEM FOR TRANSFERRING A MORE OR LESS VISCOUS LIQUID PRODUCT ONTO A MEDIUM, METHOD FOR MANUFACTURING SUCH A SURFACE AND OFFSET PRINTING BLANKET PRODUCED WITH THIS SURFACE
US5670161A (en) 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
US5811272A (en) 1996-07-26 1998-09-22 Massachusetts Institute Of Technology Method for controlling molecular weight of polyhydroxyalkanoates
US6245537B1 (en) 1997-05-12 2001-06-12 Metabolix, Inc. Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
CA2303070C (en) * 1997-09-19 2011-03-15 Metabolix, Inc. Biological systems for manufacture of polyhydroxylalkanoate polymers containing 4-hydroxyacids
WO1999032536A1 (en) 1997-12-22 1999-07-01 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
JP2002516384A (en) * 1998-05-22 2002-06-04 メタボリックス,インコーポレイテッド Polyhydroxyalkanoate biopolymer composition
ES2295021T3 (en) * 1999-03-25 2008-04-16 Metabolix, Inc. USE AND MEDICAL APPLICATIONS OF POLYMER POLYMERS (HYDROXIALCANOATS).
US6368346B1 (en) 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
ITTO20010061A1 (en) 2001-01-25 2002-07-25 Novamont Spa BINARY MIXTURES OF BIODEGRADABLE ALIPHATIC POLYESTERS AND PRODUCTS OBTAINED FROM THESE.
US6905987B2 (en) * 2001-03-27 2005-06-14 The Procter & Gamble Company Fibers comprising polyhydroxyalkanoate copolymer/polylactic acid polymer or copolymer blends
US6607548B2 (en) * 2001-05-17 2003-08-19 Inion Ltd. Resorbable polymer compositions
US20030069629A1 (en) 2001-06-01 2003-04-10 Jadhav Balkrishna S. Bioresorbable medical devices
WO2003063733A1 (en) 2002-01-31 2003-08-07 Radi Medical Systems Ab Stent
ES2741964T3 (en) 2002-05-10 2020-02-12 Tepha Inc Bioabsorbable polymer containing 2-hydroxy acid monomers
US20040260386A1 (en) 2003-01-31 2004-12-23 Shalaby Shalaby W. Absorbable / biodegradable tubular stent and methods of making the same
US7807722B2 (en) * 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
US20050137678A1 (en) * 2003-12-22 2005-06-23 Medtronic Vascular, Inc. Low profile resorbable stent
US20060018948A1 (en) 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US20060069629A1 (en) * 2004-09-30 2006-03-30 Michael Schweitzer Methods and systems for redeploying stock in a distribution network
WO2007092418A2 (en) * 2006-02-07 2007-08-16 Tepha, Inc. Polymeric, degradable drug-eluting stents and coatings

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728839A (en) * 1971-04-29 1973-04-24 American Cyanamid Co Storage stable surgically absorbable polyglycolic acid products
US4950258A (en) * 1988-01-28 1990-08-21 Japan Medical Supply Co., Ltd. Plastic molded articles with shape memory property
EP0753539A1 (en) * 1995-07-13 1997-01-15 Mitsubishi Gas Chemical Company, Inc. Aliphatic polyester polymer blends based on poly(lactic acid), methods for manufacturing the same, and methods for molding the same

Also Published As

Publication number Publication date
US7618448B2 (en) 2009-11-17
WO2007092418A3 (en) 2008-08-14
ES2395076T3 (en) 2013-02-08
WO2007092417A1 (en) 2007-08-16
EP1991287B1 (en) 2012-07-04
US20070185561A1 (en) 2007-08-09
EP1993621B1 (en) 2011-08-17
JP5508720B2 (en) 2014-06-04
ES2395112T3 (en) 2013-02-08
CA2640750A1 (en) 2007-08-16
US20160355637A1 (en) 2016-12-08
EP1991287A2 (en) 2008-11-19
AU2007212501A1 (en) 2007-08-16
JP2009525812A (en) 2009-07-16
ATE520425T1 (en) 2011-09-15
WO2007092418A2 (en) 2007-08-16
CA2640750C (en) 2013-12-17
AU2007212501B2 (en) 2011-03-31
EP1993621A1 (en) 2008-11-26
US20070182041A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
US20160355677A1 (en) Toughened polylactic acid polymers and copolymers
US10227718B2 (en) Medical devices containing dry spun non-wovens of poly-4-hydroxybutyrate and copolymers
Hamad et al. Properties and medical applications of polylactic acid: A review.
US7943683B2 (en) Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
Sheth et al. Biodegradable polymer blends of poly (lactic acid) and poly (ethylene glycol)
US8287909B2 (en) Medical devices containing melt-blown non-wovens of poly-4-hydroxybutyrate and copolymers thereof
US9737629B2 (en) Mechanically strong absorbable polymeric blend compositions of precisely controllable absorption rates, processing methods, and products therefrom
Meinander et al. Polylactides‐degradable polymers for fibres and films
US10058637B2 (en) Absorbable polymeric blend compositions with precisely controllable absorption rates, processing methods, and dimensionally stable medical devices therefrom
US9259514B2 (en) Absorbable polymeric blend compositions based on copolymers prepared from mono- and di-functional polymerization initiators, processing methods, and medical devices therefrom
US20130309166A1 (en) Injection Molding of Poly-4-Hydroxybutyrate
US9181427B2 (en) Absorbable bimodal polymeric blend compositions, processing methods, and medical devices
US7652127B2 (en) Absorbable copolyesters of poly(ethoxyethylene diglycolate) and glycolide
US9302029B2 (en) Pultrusion of poly-4-hydroxybutyrate and copolymers thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEPHA, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIZK, SAID;MARTIN, DAVID P.;HO, KICHERL;AND OTHERS;SIGNING DATES FROM 20070216 TO 20070222;REEL/FRAME:039497/0084

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION